Search Results

Business

ExcellGene SA and Cytovance Biologics Join Forces to Transform Large Molecule Biologics Development and Manufacture

ExcellGene SA proudly announces its strategic collaboration with Cytovance Biologics, a renowned Contract Development and Manufacturing Organization based in the USA.

May 8, 2024

·

3 min read

Press Releases

Cytovation to present full safety and efficacy data from the CICILIA Phase I/IIa trial evaluating CY-101 in solid tumors at ESMO 2024

September 13, 2024

·

3 min read

Business

Cytovation Announces Appointment of Ellen Lubman, MBA to its Board of Directors

Cytovation ASA, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumour membrane immunotherapy CyPep-1, announced the election of Ellen Lubman, MBA, to its Board of Directors.

December 20, 2023

·

3 min read

Cytovance Biologics and Alcami Unite to Deliver End-to-End Solutions for Biologics Developers

Cytovance Biologics has announced a strategic collaboration with fellow CDMO Alcami Corporation to expand its large molecule biologic manufacturing and sterile fill finish offering.

December 11, 2023

·

3 min read

Cytovance Biologics Announces Dr. Axel Schleyer to Expand Footprint and Service Offering as Chief Commercial Officer

Cytovance Biologics, a leading full-service mammalian and microbial large molecule contract development and manufacturing organization (CDMO), announced today the addition of Axel Schleyer, Ph.D., MBA,

September 26, 2023

·

2 min read

Large Molecule CDMO, Cytovance Biologics, and Custom Strain Development Expert, Vectron Biosolutions, Partner to Improve Development of Complex Microbial Molecules

Cytovance Biologics announced a strategic, international collaboration with Vectron Biosolutions to add customized E. coli strain development to the CDMO’s microbial program.

October 10, 2023

·

5 min read

Business

Cytovation appoints Olav Hellebø to its Board of Directors

Cytovation ASA, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumor membrane immunotherapy CyPep-1, announces the appointment of Olav Hellebø to its Board of Directors.

July 5, 2023

·

2 min read

Drug Development

Cytovation Reports Promising Interim Results from Phase 1/2a CICILIA Study with CyPep-1 in Solid Tumors

Cytovation ASA, a clinical stage immune-oncology company focused on the development of CyPep-1, its first-in-class, dual-acting targeted tumor immunotherapy, announces positive initial data from Part 2 of its Phase 1/2a CICILIA basket trial with all trial endpoints met.

October 11, 2023

·

3 min read

Business

Cytovance Biologics Announces Ping Zhang as Chief Executive Officer

Cytovance® Biologics announces the appointment of Mr. Ping Zhang as Chief Executive Officer.

January 16, 2023

·

2 min read

Business

Cytovance Biologics and Phenotypeca Collaborate to Enhance Saccharomyces cerevisiae Strain Development for Microbial Biomanufacturing

Cytovance Biologics, Inc. and Phenotypeca Limited have entered into an agreement to provide optimized Saccharomyces cerevisiae strains for biopharmaceutical manufacturing.

March 11, 2023

·

3 min read